바이오의약품 첨가제 제조 시장(제2판) : 사업 규모, 치료법, 첨가제, 화학성분, 기업 규모, 제조 기반, 최종사용자, 지역별 동향 및 예측(-2035년)

BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global biopharmaceutical excipient manufacturing market is estimated to grow from USD 3.6 billion in the current year to USD 6.3 billion by 2035, at a CAGR of 6.4% during the forecast period, till 2035.

Biopharmaceutical Excipient Manufacturing Market: Growth and Trends

Biologics are emerging as advanced therapeutics to treat broad range of chronic diseases. Moreover, the pipeline of biological candidates under active clinical investigation has expanded sharply over the past decade. Monoclonal antibodies, recombinant proteins, vaccines, and gene therapies are gaining preference over small molecules because of their higher target specificity and better safety profiles. Owing to the high target specificity, these monoclonal antibodies are gaining momentum across oncology, autoimmune disease, and rare and genetic disorders.

It is worth noting that biologics are inherently unstable due to their structure complexity. These molecules are prone to physical degradation such as aggregation, precipitation, and denaturation, as well as chemical degradation such as oxidation, deamidation, and hydrolysis, across manufacturing, storage, and distribution. Biopharmaceutical excipients, including sugars, amino acids, surfactants, and polymeric agents, are formulated alongside these molecules to preserve conformation, control pH and tonicity, and extend shelf life. Polysorbates are widely used in marketed biologics, while bulking agents, antioxidants, and preservatives support formulation stability and performance.

As drug developers shift toward lyophilized vials, prefilled syringes, and ready-to-use liquid formats, the demands placed on excipient purity and functional consistency continue to rise. mRNA-based vaccines and therapeutics are adding a distinct branch to this landscape, with lipid-based excipients emerging as a fast-growing sub-category. Combined with an industry-wide move towards outsourced formulation development and more accommodating regulatory pathways for novel excipients, this diversification is expected to sustain manufacturing capacity growth through 2035.

Growth Drivers: Factors Fueling Market Expansion

The biopharmaceutical excipient manufacturing market is being driven by the rising global burden of chronic diseases, which continues to expand the demand for monoclonal antibodies, recombinant proteins, vaccines, and gene therapies, each dependent on tailored excipient systems. Growing strategic collaboration between excipient producers and biopharmaceutical sponsors, broadening regulatory acceptance of novel excipients, and steady expansion of GMP-compliant manufacturing infrastructure are reinforcing this trajectory. Rising interest in probiotic-based and microbiome-targeted therapeutics is also generating incremental demand for excipients capable of preserving live biological activity through formulation, fill-finish, and storage. These initiatives have further widened the addressable market for manufacturers and their distribution partners.

Market Challenges: Critical Barriers Hindering Progress

Despite favourable growth conditions, excipient manufacturers and their distribution partners face a capital-intensive path to expansion. Building and validating GMP-required, endotoxin-controlled production lines requires substantial upfront investment, and stringent, evolving quality regulations raise the bar for market entry.

Limited availability of investment capital for capacity expansion remains a persistent constraint for several mid-sized players, while the absence of a fully harmonized global regulatory pathway for genuine novel excipients continue to slow their commercial adoption. For distributors, the added need to maintain dedicated cold chain and low-bioburden storage infrastructure for specialty excipients, particularly the lipid-based agents used in mRNA formulations, introduces a further layer of operational complexity.

Biopharmaceutical Excipient Manufacturing Market: Key Insights

The report delves into the current state of the biopharmaceutical excipient manufacturing market and identifies potential growth opportunities within the industry. Some key findings include:

• Excipient manufacturers have historically relied on direct B2B contracts to serve large pharmaceutical accounts, but specialty chemical distributors such as IMCD, Univar Solutions, and Azelis are playing a growing intermediary role in extending GMP-grade excipient access to mid-sized biopharma companies and contract development and manufacturing organizations (CDMOs).
• Distributors seeking entry into qualified supplier networks must demonstrate IPEC-GMP or ExCiPact-aligned handling practices, controlled and traceable storage, and documentation packages that satisfy sponsor CMC teams, mirroring the accreditation bar already established across specialty biologics distribution.
• The shift toward endotoxin-controlled, high-purity excipients is raising the qualification bar for distribution partners, since any lapse in traceability or storage integrity can trigger rejection of an entire formulation batch further down the supply chain.
• The expansion of mRNA and lipid nanoparticle (LNP)-based therapeutics is driving demand for temperature-controlled distribution of lipid excipients. This trend is prompting capacity investments by Evonik and BASF Pharma and increasing the need for robust cold-chain infrastructure to support the storage and transportation of temperature-sensitive biologics.
• Contract manufacturers are increasingly integrating excipient sourcing and formulation support into their service offerings. This trend is illustrated by DFE Pharma's continuous manufacturing platform launch, which is gradually blurring the line between traditional distribution and CDMO partnership models.
• Because approved biologic formulations lock in specific excipient grades through comparability protocols, distributors that secure early-stage preclinical and clinical accounts are well positioned to convert them into long-term, high-volume commercial supply contracts, creating durable, recurring revenue visibility.
• Small and mid-sized biopharmaceutical companies increasingly lean on distributor-provided technical and regulatory support, including drug master file (DMF) referencing and documentation packages, elevating the distributor's role well beyond pure logistics and order fulfilment.
• Sole distribution agreements, such as Ashland's expanded global arrangement to distribute Wacker Chemie's cyclodextrin excipients, are becoming a preferred go-to-market model for specialty excipient producers seeking global reach without direct investment in sales infrastructure, opening a clear playbook for distributors to pursue similar exclusivity arrangements.

Biopharmaceutical Excipient Manufacturing Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Scale of Operation

• Preclinical / Clinical Scale
• Commercial Scale

By Type of Modality

• Antibodies
• Vaccines
• Cell and Gene Therapies
• Proteins / Peptides
• Other Biologics

By Type of Excipient

• Buffering Agents
• Lyoprotectant Agents
• Solubilizers and Surfactants
• Tonicity Agents
• pH Adjusting Agents
• Others

By Chemical Components

• Carbohydrates
• Polymers
• Polyols
• Proteins / Amino Acids
• Others

By Company Size

• Small Players
• Mid-sized Players
• Large and Very Large Players

By Source of Manufacturing

• In-house
• Outsourcing

By End User

• Contract Manufacturers
• Pharmaceutical Companies
• Hybrid Players

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Australia

Biopharmaceutical Excipient Manufacturing Market: Key Segmentation Insights

Commercial Scale Operations Leads the Market

Based on our market assessment, commercial-scale operations hold nearly 90% share of the market and also register a higher CAGR of 6.8% during the forecast period. This dominance reflects the growing number of biologic therapies, particularly monoclonal antibodies, recombinant proteins, and vaccines, transitioning out of clinical development into full-scale commercial manufacturing. With the growing number of biologics, excipient demand becomes large-volume, consistent, and recurring rather than sporadic.

Notably, regulatory comparability requirements make post-approval excipient changes challenging and expensive. Consequently, biopharmaceutical companies tend to establish long-term partnerships with manufacturers that offer proven GMP compliance, robust quality management, and reliable supply continuity.

Buffering Agents Hold the Lead, Solubilizers and Surfactants Set the Pace

According to our market analysis, buffering agents occupy the largest share among excipient types. This highest share can be attributed to their role across the entire biologic lifecycle, from formulation development and stability testing through fill-finish and downstream processing.

Their function in maintaining pH-dependent protein conformation and controlling aggregation gives them near-universal adoption across modalities. Solubilizers and surfactants, meanwhile, are set to register the fastest growth, as the industry's shift toward high-concentration subcutaneous formulations increases the need for agents that manage viscosity, solubility, and colloidal stability.

Antibodies Dominate the Market

Based on our proprietary market report, antibodies represent the largest modality segment by revenue, a position built on the sheer scale of approved monoclonal antibody therapies and a deep pipeline spanning oncology and immunology. Their large, structurally complex protein architecture makes them inherently prone to physical and chemical instability across manufacturing, storage, and administration, requiring more sophisticated excipient systems than simpler modalities and supporting a higher projected CAGR of 8.7% for the segment through 2035.

In-House Manufacturing Leads the Market

Based on our proprietary market report, in-house manufacturing retains the largest share of the market. This dominance is attributed to the growing importance of excipient quality, traceability, and supply continuity in CMC compliance, prompting biopharmaceutical companies to maintain long-term relationships with trusted suppliers to reduce regulatory risk.

Outsourcing, however, is projected to grow at the fastest pace, as pharmaceutical companies look to reduce capital expenditure and gain flexibility in managing variable demand without heavy investment in dedicated in-house excipient production or testing capacity. Therefore, the growing shift toward outsourcing is strengthening the role of well-qualified distribution partners with proven technical expertise and reliable supply capabilities.

Europe Dominates the Market, While Asia-Pacific Registers the Highest CAGR

Europe holds the largest regional share, close to 35%, supported by a high concentration of established biotech and pharmaceutical manufacturers, mature R&D infrastructure, and a supportive regulatory environment. Asia-Pacific, in contrast, is projected to register the highest CAGR of 7.7% through 2035. This highest CAGR is due to the fact that China and South Korea are scaling up biomanufacturing capacity and government-backed initiatives. Moreover, India's production-linked incentive scheme and China's advanced manufacturing policy agenda, accelerate demand for high-quality excipients across injectable, lyophilized, and high-concentration biologic formulations.

Carbohydrates Hold the Highest Market Share

Carbohydrates, including sucrose, starch, and dextrose, currently hold the largest share among chemical components. This highest share reflects their broad use across drug formulations and recent innovation such as injectable-grade sucrose designed for mRNA vaccine and lipid nanoparticle stabilization.

Polymers segment is expected to grow at a higher CAGR of 7.1% during the forecast period. This growth is largely because high-purity grades, including biodegradable and stimuli-responsive polymers, allow manufacturers to command premium pricing while addressing formulation challenges such as aggregation and cold-chain dependency.

Example Players in Biopharmaceutical Excipient Manufacturing Market

• Avantor
• Spectrum Chemical Manufacturing
• Actylis
• Pfanstiehl
• Biospectra
• BOC Sciences
• Merck KGaA
• CG Chemkalien
• Evonik
• BASF Pharma
• Mass Chemicals
• Gangwal
• Mitushi Biopharma
• Nagase Viita

BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biopharmaceutical excipient manufacturing market, focusing on key segments, including scale of operation, type of modality, type of excipient, chemical components, company size, source of manufacturing, end user, and geographical regions.
• Manufacturer Landscape: A detailed assessment of biopharmaceutical excipient manufacturers, featuring information on parameters such as year of establishment, company size, location of headquarters, certification status, and product portfolio breadth.
• Company Profiles: In-depth profiles of prominent players engaged in the manufacturing and manufacturing of biopharmaceutical excipients, featuring information on their year of establishment, location of headquarters, company size, management team, portfolio, and key initiatives.
• Partnerships and Collaborations: An analysis of partnerships and collaborations that have been inked by biopharmaceutical excipient manufacturers, based on several relevant parameters, such as such as year of partnership, type of partnership, type of excipient, and most active players.
• Recent Expansions: A detailed analysis of recent expansions in this industry based on several parameters, including year of expansions, type of expansion, year and type of expansion, location of expanded facility (region), location of expanded facility (country), and most active players.
• Capacity Analysis: A qualitative analysis of installed global capacity covered based on company size, scale of operation, and location of manufacturing facility.
• Vendor Selection Framework: A detailed assessment of the vendor selection framework for isotope manufacturing, highlighting the strategic drivers for outsourcing, the operations most commonly outsourced, and the key technical, regulatory, commercial, and operational parameters used to evaluate service providers.
• Market Impact Analysis: The report also covers analysis of drivers, restraints, opportunities, and challenges affecting market growth.

Key Questions Answered in this Report

• Which are the leading companies in the biopharmaceutical excipient manufacturing market?
• Which region dominates the biopharmaceutical excipient manufacturing market?
• What are the key trends observed in the biopharmaceutical excipient manufacturing market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by biopharmaceutical excipient manufacturers and distributors?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?
• What accreditation and infrastructure benchmarks must distributors meet to enter this market?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

• Complementary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
  • 2.2.1. Market Landscape and Market Trends
  • 2.2.2. Market Forecast and Opportunity Analysis
  • 2.2.3. Comparative Analysis
• 2.3. Database Building
  • 2.3.1. Data Collection
  • 2.3.2. Data Validation
  • 2.3.3. Data Analysis
• 2.4. Project Methodology
  • 2.4.1. Secondary Research
    • 2.4.1.1. Annual Reports
    • 2.4.1.2. Academic Research Papers
    • 2.4.1.3. Company Websites
    • 2.4.1.4. Investor Presentations
    • 2.4.1.5. Regulatory Filings
    • 2.4.1.6. White Papers
    • 2.4.1.7. Industry Publications
    • 2.4.1.8. Conferences and Seminars
    • 2.4.1.9. Government Portals
    • 2.4.1.10. Media and Press Releases
    • 2.4.1.11. Newsletters
    • 2.4.1.12. Industry Databases
    • 2.4.1.13. Roots Proprietary Databases
    • 2.4.1.14. Paid Databases and Sources
    • 2.4.1.15. Social Media Portals
    • 2.4.1.16. Other Secondary Sources
  • 2.4.2. Primary Research
    • 2.4.2.1. Types of Primary Research
      • 2.4.2.1.1. Qualitative Research
      • 2.4.2.1.2. Quantitative Research
      • 2.4.2.1.3. Hybrid Approach
    • 2.4.2.2. Advantages of Primary Research
    • 2.4.2.3. Techniques for Primary Research
      • 2.4.2.3.1. Interviews
      • 2.4.2.3.2. Surveys
      • 2.4.2.3.3. Focus Groups
      • 2.4.2.3.4. Observational Research
      • 2.4.2.3.5. Social Media Interactions
    • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
      • 2.4.2.4.1. Company Executives (CXOs)
      • 2.4.2.4.2. Board of Directors
      • 2.4.2.4.3. Company Presidents and Vice Presidents
      • 2.4.2.4.4. Research and Development Heads
      • 2.4.2.4.5. Technical Experts
      • 2.4.2.4.6. Subject Matter Experts
      • 2.4.2.4.7. Scientists
      • 2.4.2.4.8. Doctors and Other Healthcare Providers
    • 2.4.2.5. Ethics and Integrity
      • 2.4.2.5.1. Research Ethics
      • 2.4.2.5.2. Data Integrity
  • 2.4.3. Analytical Tools and Databases
• 2.5. Robust Quality Control

3. MARKET DYNAMICS

• 3.1. Chapter Overview
• 3.2. Forecast Methodology
  • 3.2.1. Top-down Approach
  • 3.2.2. Bottom-up Approach
  • 3.2.3. Hybrid Approach
• 3.3. Market Assessment Framework
  • 3.3.1. Total Addressable Market (TAM)
  • 3.3.2. Serviceable Addressable Market (SAM)
  • 3.3.3. Serviceable Obtainable Market (SOM)
  • 3.3.4. Currently Acquired Market (CAM)
• 3.4. Forecasting Tools and Techniques
  • 3.4.1. Qualitative Forecasting
  • 3.4.2. Correlation
  • 3.4.3. Regression
  • 3.4.4. Extrapolation
  • 3.4.5. Convergence
  • 3.4.6. Sensitivity Analysis
  • 3.4.7. Scenario Planning
  • 3.4.8. Data Visualization
  • 3.4.9. Time Series Analysis
  • 3.4.10. Forecast Error Analysis
• 3.5. Key Considerations
  • 3.5.1. Demographics
  • 3.5.2. Government Regulations
  • 3.5.3. Reimbursement Scenarios
  • 3.5.4. Market Access
  • 3.5.5. Supply Chain
  • 3.5.6. Industry Consolidation
  • 3.5.7. Pandemic / Unforeseen Disruptions Impact
• 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

• 4.1. Chapter Overview
• 4.2. Market Dynamics
  • 4.2.1. Time Period
    • 4.2.1.1. Historical Trends
    • 4.2.1.2. Current and Forecasted Estimates
  • 4.2.2. Currency Coverage
    • 4.2.2.1. Major Currencies Affecting the Market
    • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
    • 4.2.2.3. Impact of Currency Fluctuations on the Industry
  • 4.2.3. Foreign Currency Exchange Rate
    • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
    • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 4.2.4. Recession
    • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
  • 4.2.5. Inflation
    • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
  • 4.2.6. Interest Rates
    • 4.2.6.1. Interest Rates and Their Impact on the Market
    • 4.2.6.2. Strategies for Managing Interest Rate Risk
  • 4.2.7. Commodity Flow Analysis
    • 4.2.7.1. Type of Commodity
    • 4.2.7.2. Origins and Destinations
    • 4.2.7.3. Values and Weights
    • 4.2.7.4. Modes of Transportation
  • 4.2.8. Global Trade Dynamics
    • 4.2.8.1. Import Scenario
    • 4.2.8.2. Export Scenario
    • 4.2.8.3. Trade Policies
    • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
    • 4.2.8.5. Impact of Trade Barriers on the Market
  • 4.2.9. War Impact Analysis
    • 4.2.9.1. Russian-Ukraine War
    • 4.2.9.2. Israel-Hamas War
  • 4.2.10. COVID Impact / Related Factors
    • 4.2.10.1. Global Economic Impact
    • 4.2.10.2. Industry-specific Impact
    • 4.2.10.3. Government Response and Stimulus Measures
    • 4.2.10.4. Future Outlook and Adaptation Strategies
  • 4.2.11. Other Indicators
    • 4.2.11.1. Fiscal Policy
    • 4.2.11.2. Consumer Spending
    • 4.2.11.3. Gross Domestic Product
    • 4.2.11.4. Employment
    • 4.2.11.5. Taxes
    • 4.2.11.6. Stock Market Performance
    • 4.2.11.7. Cross Border Dynamics
• 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

• 6.1. Chapter Overview
• 6.2. Biopharmaceutical Excipients
• 6.3. Properties of Ideal Excipients
• 6.4. Classification of Biopharmaceutical Excipients
  • 6.4.1. Classification of Excipients based on Route of Administration
  • 6.4.2. Classification of Excipients based on Structure
  • 6.4.3. Classification of Excipients based on Function
  • 6.4.4. Classification of Excipients based on Ability to Interfere with Metabolization and Efflux Mechanisms
• 6.5. Applications of Biopharmaceutical Excipients
• 6.6. Regulatory Scenario
• 6.7. Concluding Remarks

7. MARKET LANDSCAPE: BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURERS

• 7.1. Chapter Overview
• 7.2. Biopharmaceutical Excipients Manufacturers: Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Company Size
  • 7.2.3. Analysis by Location of Headquarters
  • 7.2.4. Analysis by Location of Headquarters and Company Size
  • 7.2.5. Analysis by Location of Manufacturing Facilities (Region)
  • 7.2.6. Analysis by Scale of Operation
  • 7.2.7. Analysis by Type of Excipient based on Chemical Composition
  • 7.2.8. Analysis by Type of Excipient based on Function
  • 7.2.9. Analysis by Type of Chemical Structure of Excipient
  • 7.2.10. Analysis by Type of Formulation
  • 7.2.11. Analysis by Type of Biologic
  • 7.2.12. Analysis by Global Regulatory Compliance

8. COMPANY COMPETITIVENESS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Key Parameters
• 8.3. Methodology
• 8.4. Overview of Peer Groups
• 8.5. Company Competitiveness Analysis
  • 8.5.1. Biopharmaceutical Excipient Manufacturers Headquartered in North America
  • 8.5.2. Biopharmaceutical Excipient Manufacturers Headquartered in Europe
  • 8.5.3. Biopharmaceutical Excipient Manufacturers Headquartered in Asia-Pacific

9. BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS: COMPANY PROFILES OF PLAYERS BASED IN NORTH AMERICA

• 9.1. Chapter Overview
• 9.2. Avantor
  • 9.2.1. Company Overview
  • 9.2.2. Financial Information
  • 9.2.3. Biopharmaceutical Excipient Offerings
  • 9.2.4. Manufacturing Facilities
  • 9.2.5. Recent Developments and Future Outlook
• 9.3. Spectrum Chemical Manufacturing
• 9.4. Actylis
• 9.5. Pfanstiehl
• 9.6. Biospectra
• 9.7. BOC Sciences

10. BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS: COMPANY PROFILES OF PLAYERS BASED IN EUROPE

• 10.1. Chapter Overview
• 10.2. Merck KGaA
  • 10.2.1. Company Overview
  • 10.2.2. Financial Information
  • 10.2.3. Biopharmaceutical Excipient Offerings
  • 10.2.4. Manufacturing Facilities
  • 10.2.5. Recent Developments and Future Outlook
• 10.3. CG Chemkalien
• 10.4. Evonik
• 10.5. BASF Pharma

11. BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS: COMPANY PROFILES OF PLAYERS BASED IN ASIA-PACIFIC

• 11.1. Chapter Overview
• 11.2. Mass Chemicals
  • 11.2.1. Company Overview
  • 11.2.2. Financial Information
  • 11.2.3. Biopharmaceutical Excipient Offerings
  • 11.2.4. Manufacturing Facilities
  • 11.2.5. Recent Developments and Future Outlook
• 11.3. Gangwal
• 11.4. Mitushi Biopharma
• 11.5. Nagase Vitta

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnership Models
• 12.3. Biopharmaceutical Manufacturers: Partnerships and Collaborations
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Type of Excipient
  • 12.3.5. Most Active Players: Analysis by Number of Partnerships
  • 12.3.6. Analysis by Geography
    • 12.3.6.1. Local and International Agreements
    • 12.3.6.2. Intracontinental and Intercontinental Agreements

13. RECENT EXPANSIONS

• 13.1. Chapter Overview
• 13.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
  • 13.2.1. Analysis by Year of Expansion
  • 13.2.2. Analysis by Type of Expansion
  • 13.2.3. Analysis by Year and Type of Expansion
  • 13.2.4. Analysis by Type of Excipient
  • 13.2.5. Analysis by Type of Expansion (Country)
  • 13.2.6. Analysis by Location of Expanded Facility (Region)
  • 13.2.7. Analysis by Location of Expanded Facility (Country)
  • 13.2.8. Analysis by Type of Expansion and Location of Manufacturing Facility
  • 13.2.9. Most Active Players: Analysis by Number of Recent Expansions
  • 13.2.10. Geographical Analysis

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
  • 14.3.1. Analysis by Company Size
  • 14.3.2. Analysis by Scale of Operation
  • 14.3.3. Analysis by Location of Manufacturing Facility
• 14.4. Concluding Remarks

15. VENDOR SELECTION FRAMEWORK

• 15.1. Reasons to Outsource in Isotope Manufacturing
• 15.2. Commonly Outsourced Operations in Isotope Manufacturing
• 15.3. Key Parameters
• 15.4. Methodology for Vendor Selection Framework
• 15.5. Benchmarking of Parameters
• 15.6. Value Addition vs Evaluation Complexity Matrix
• 15.7. Case Study Assessment of Merck
• 15.8. Overview of Vendor Assessment Dashboard
  • 15.8.1. Scenario I
  • 15.8.2. Scenario II
  • 15.8.3. Scenario III

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges
• 16.6. Conclusion

17. GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET

• 17.1. Chapter Overview
• 17.2. Assumptions and Methodology
• 17.3. Biopharmaceutical Excipients Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 17.3.1. Roots Analysis Perspective on Market Growth
  • 17.3.2. Scenario Analysis
    • 17.3.2.1. Conservative Scenario
    • 17.3.2.2. Optimistic Scenario
• 17.4. Key Market Segmentations

18. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY SCALE OF OPERATION

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Scale of Operation
  • 18.3.1. Biopharmaceutical Excipients Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 18.3.2. Biopharmaceutical Excipients Manufacturing Market for Commercial Scale, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY TYPE OF MODALITY

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Type of Modality
  • 19.3.1. Biopharmaceutical Excipients Manufacturing Market for Antibodies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 19.3.2. Biopharmaceutical Excipients Manufacturing Market for Vaccines, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 19.3.3. Biopharmaceutical Excipients Manufacturing Market for Cell and Gene Therapies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 19.3.4. Biopharmaceutical Excipients Manufacturing Market for Proteins / Peptides, Historical Trends (since 2021) and Forecasted Estimate, (till 2035)
  • 19.3.5. Biopharmaceutical Excipients Manufacturing Market for Other Biologics, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY TYPE OF EXCIPIENT

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Type of Excipient
  • 20.3.1. Biopharmaceutical Excipients Manufacturing Market for Buffering Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.2. Biopharmaceutical Excipients Manufacturing Market for Lyoprotectant Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.3. Biopharmaceutical Excipients Manufacturing Market for Solubilizers and Surfactants, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.4. Biopharmaceutical Excipients Manufacturing Market for Tonicity Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.2. Biopharmaceutical Excipients Manufacturing Market for pH Adjusting Agents, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.3. Biopharmaceutical Excipients Manufacturing Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 20.4. Data Triangulation and Validation

21. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY CHEMICAL COMPONENTS

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Chemical Components
  • 21.3.1. Biopharmaceutical Excipients Manufacturing Market for Carbohydrates, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 21.3.2. Biopharmaceutical Excipients Manufacturing Market for Polymers, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 21.3.3. Biopharmaceutical Excipients Manufacturing Market for Polyols, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 21.3.4. Biopharmaceutical Excipients Manufacturing Market for Proteins / Amino Acids, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 21.3.5. Biopharmaceutical Excipients Manufacturing Market for Others, Historical Trends (since 2021)and Forecasted Estimates (till 2035)
• 21.4. Data Triangulation and Validation

22. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY COMPANY SIZE

• 22.1. Chapter Overview
• 22.2. Key Assumptions and Methodology
• 22.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Company Size
  • 22.3.1. Biopharmaceutical Excipients Manufacturing Market for Small Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 22.3.2. Biopharmaceutical Excipients Manufacturing Market for Mid-sized Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 22.3.3. Biopharmaceutical Excipients Manufacturing Market for Large and Very Large Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 22.4. Data Triangulation and Validation

23. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY SOURCE OF MANUFACTURING

• 23.1. Chapter Overview
• 23.2. Key Assumptions and Methodology
• 23.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Source of Manufacturing
  • 23.3.1. Biopharmaceutical Excipients Manufacturing Market for In-house, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 23.3.2. Biopharmaceutical Excipients Manufacturing Market for Outsourcing, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 23.4. Data Triangulation and Validation

24. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY END USER

• 24.1. Chapter Overview
• 24.2. Key Assumptions and Methodology
• 24.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by End User
  • 24.3.1. Biopharmaceutical Excipients Manufacturing Market for Contract Manufacturers, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 24.3.2. Biopharmaceutical Excipients Manufacturing Market for Pharmaceutical Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 24.3.3. Biopharmaceutical Excipients Manufacturing Market for Hybrid Players, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 24.4. Data Triangulation and Validation

25. BIOPHARMACEUTICAL EXCIPIENTS MANUFACTURING MARKET, BY GEOGRAPHICAL REGIONS

• 25.1. Chapter Overview
• 25.2. Key Assumptions and Methodology
• 25.3. Biopharmaceutical Excipients Manufacturing Market: Distribution by Geographical Regions
  • 25.3.1. Biopharmaceutical Excipients Manufacturing Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.1.1. Biopharmaceutical Excipients Manufacturing Market in the US, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.1.2. Biopharmaceutical Excipients Manufacturing Market in Canada, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 25.3.2. Biopharmaceutical Excipients Manufacturing Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.2.1. Biopharmaceutical Excipients Manufacturing Market in France, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.2.2. Biopharmaceutical Excipients Manufacturing Market in Germany, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.2.3. Biopharmaceutical Excipients Manufacturing Market in Italy, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.2.4. Biopharmaceutical Excipients Manufacturing Market in Spain, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.2.5. Biopharmaceutical Excipients Manufacturing Market in the UK, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.2.6. Biopharmaceutical Excipients Manufacturing Market in Rest of Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 25.3.3. Biopharmaceutical Excipients Manufacturing Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.3.1. Biopharmaceutical Excipients Manufacturing Market in China, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.3.2. Biopharmaceutical Excipients Manufacturing Market in India, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.3.3. Biopharmaceutical Excipients Manufacturing Market in South Korea, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.3.4. Biopharmaceutical Excipients Manufacturing Market in Japan, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.3.5. Biopharmaceutical Excipients Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 25.3.4. Biopharmaceutical Excipients Manufacturing Market in Middle East and Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.4.1. Biopharmaceutical Excipients Manufacturing Market in Saudi Arabia, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.4.2. Biopharmaceutical Excipients Manufacturing Market in UAE, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.4.3. Biopharmaceutical Excipients Manufacturing Market in Egypt, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 25.3.5. Biopharmaceutical Excipients Manufacturing Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.5.1. Biopharmaceutical Excipients Manufacturing Market in Brazil, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.5.2. Biopharmaceutical Excipients Manufacturing Market in Mexico, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 25.3.5.3. Biopharmaceutical Excipients Manufacturing Market in Rest of Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 25.4. Biopharmaceutical Excipients Manufacturing Market, by Geographical Regions: Market Dynamics Assessment
  • 25.4.1. Penetration Growth (P-G) Matrix
  • 25.4.2. Market Movement Analysis

26. CONCLUDING INSIGHTS

27. EXECUTIVE INSIGHTS

28. APPENDIX I: TABULATED DATA